Medtronic launches Intellis spinal cord neurostimulation platform which includes the world's smallest fully implantable spinal cord neurostimulator to treat pain.
Medtronic received 510(k) FDA approval on 11 July 2017 and is now releasing in the U.S. its Intellis spinal cord neurostimulation platform, which includes the world’s smallest fully implantable spinal cord neurostimulator. The system delivers both high-dose and low-dose therapy, depending on the patient’s needs, and tracks patient activity to help physicians improve how the therapy targets individual’s pain.
It is made to wirelessly, and securely, interface with a Samsung Galaxy Tab S2 tablet which is used by the physician to adjust settings and set parameters that best address the patient’s needs. The same tablet can be used to upgrade the neurostimulator implant with new versions of its firmware.
The company hopes that neurostimulation will have an impact on the opioid epidemic that the United States, as well as many other countries, are facing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins